Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 11 July 2013 | By Alexander Gaffney, RAC,
The Critical Path Institute (C-Path), a public-private hybrid organization supported directly by the US Food and Drug Administration (FDA), has announced a "big step forward for Alzheimer's disease therapy development," saying that it has obtained the support of FDA and the European Medicines Agency (EMA) to launch a new disease simulation tool intended to improve clinical trial design for investigating Alzheimer's treatments.
C-Path, which was founded in 2005 under FDA's Critical Path Initiative, is behind a number of initiatives meant to expedite drug development by focusing on common bottlenecks in the development process. In September 2012, for example, it announced the launch of a new "breakthrough tool" intended to help combine data from multiple studies, standardizing the way companies report data from research on tuberculosis drugs. The collected data can be used to support the regulatory review process by developing new clinical trial simulation models and evaluation methods, C-Path wrote at the time.
The new Alzheimer's tool is very much in the same vein, C-Path wrote. "This new tool will make it possible to simulate clinical trials by integrating all relevant data so future studies will be more efficient and more likely to be successful."
The tool - essentially a statistical modeling system that simulates "what-if" scenarios - is "the first such instrument to ever receive this regulatory designation [from FDA]," C-Path explained. The tool obtained FDA approval on 12 June 2013, and a positive opinion from EMA's Committee on Human Medicinal Products (CHMP) on 27 June 2013.
The tool's development was reportedly supported by numerous pharmaceutical companies, which made de-identified patient-level data available to C-Path, which was then used to develop and calibrate the model. "This is a great example of a rising tide lifting all boats," wrote Richard Lalonde, global head of clinical pharmacology at Pfizer, in a statement.
The ultimate effect of the tool could be to expedite the drug approval process, C-Path explained. "The regulatory decisions on this tool exemplify how C-Path's efforts result in alignment between global regulatory agencies when based on consensus science and supporting data; an alignment that can result in greater efficiency in drug development," said Martha Brumfield, president and CEO of C-Path. And with greater efficiency should, if all goes according to plan, faster and more efficient trials that better support regulatory decisions by both FDA and EMA.
C-Path Statement
More Information
Video About the Tool
All Focus Articles on C-Path
Tags: Alzheimer's Disease, C-Path, Alzheimer's, Ad, Latest News, approval, clinical trials, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.